Published in Lab Business Week, May 1st, 2005
The acquisition will be completed as a stock transaction in which OrthoNetx shareholders will receive 1 share of Eye Dynamics stock in exchange for each share of OrthoNetx stock. The acquisition is subject to certain customary conditions including certain regulatory approvals.
As part of the transaction, Terry R. Knapp, president and CEO of OrthoNetx, will assume the position of CEO of the new, merged company. Dr. Knapp has both...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week